Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

Guangzhou ,Guangdong ,China ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,Chinese ,Denny Lanfear ,Mcdavid Stilwell ,Coherus Biosciences ,Junshi Biosciences ,Zhi Li ,Brian Grancagnolo ,Exchange Commission On ,Ir Team ,Coherus Biosciences Inc ,Drug Administration ,Shanghai Junshi Biosciences Co Ltd ,Exchange Commission ,National Reimbursement Drug List ,National Medical Products Administration ,Pr Team ,Biologics License Application ,Nasopharyngeal Carcinoma ,Southeast Asia ,New Drug Applications ,Breakthrough Therapy ,Fast Track ,Orphan Drug Designation ,Chinese Academy ,Emergency Use Authorizations ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Contact Information ,Covid 19 ,Health ,Travel ,Business ,Globe Newswire ,Lifestyle ,